BUZZ-Connect Biopharma rises as eczema drug shows lasting benefit in China study

Reuters03-30
BUZZ-<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> rises as eczema drug shows lasting benefit in China study

** Shares of biotech firm Connect Biopharma CNTB.O rise 7.9% to $3.72 premarket

** Co says its experimental drug rademikibart showed strong, lasting benefit in a year‑long late‑stage study in China in people with moderate‑to‑severe eczema, a common inflammatory skin disease

** Says nearly 90% of patients in the 52‑week study had clear or almost clear skin, while about 97% saw major reductions in disease severity

** Says the drug was well-tolerated, with side effects similar to placebo and low eye inflammation seen with rival treatments

** Adds the study was run by its China partner Simcere, which holds Greater China rights and could owe up to $110 million in milestones and royalties

** Says rademikibart is not yet approved anywhere and it is seeking partners outside China

** CNTB rose about two-fold in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment